- Nachrichtendetail
-
15.05.2024 16:00:14 - *DJ Novartis highlights pioneering innovation in CML with data from Scemblix(R) Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
(MORE TO FOLLOW) Dow Jones Newswires
May 15, 2024 10:00 ET (14:00 GMT)
May 15, 2024 10:00 ET (14:00 GMT)
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
NOVARTIS NAM. SF 0,49 | 904278 | Hamburg | 0,000 | 28.06.24 13:44:40 | ±0,000 | ±0,00% | 0,000 | 0,000 | 0,000 | 80,190 |
|
NOVARTIS NAM. ADR 1 | 907122 | Frankfurt | 98,200 | 28.06.24 08:02:46 | -0,800 | -0,81% | 98,200 | 101,000 | 98,200 | 99,000 |
